US 11,980,637 B2
Compositions comprising nanosilica particles and their use in methods of activating T lymphocytes for therapy
Jonathan Joseph Powell, Cambridge (GB); Nuno Jorge Rodrigues Faria, Milton Ernest (GB); Rachel Elaine Hewitt, Cambridge (GB); Bradley Michael Vis, Thunder Bay (CA); and Carlos Bastos, Cambridge (GB)
Assigned to United Kingdom Research and Innovation, Swindon (GB)
Filed by United Kingdom Research and Innovation, Swindon (GB)
Filed on Apr. 19, 2021, as Appl. No. 17/233,802.
Application 17/233,802 is a division of application No. 16/324,401, granted, now 11,007,217, previously published as PCT/EP2017/070183, filed on Aug. 9, 2017.
Claims priority of application No. 1613772 (GB), filed on Aug. 10, 2016; and application No. 1701827 (GB), filed on Feb. 3, 2017.
Prior Publication US 2021/0338710 A1, Nov. 4, 2021
Int. Cl. A61K 33/00 (2006.01); A61K 9/14 (2006.01); A61K 31/675 (2006.01)
CPC A61K 33/00 (2013.01) [A61K 9/14 (2013.01); A61K 31/675 (2013.01)] 20 Claims
 
1. A method for the treatment of infection comprising administering to a subject in need thereof a composition comprising silica particles having a mean diameter between 0.5 and 5 nm, wherein administration of the composition activates T lymphocytes in the subject, wherein the T lymphocytes are CD4 and/or CD8 T lymphocytes, and wherein activation of the T lymphocytes is characterised by an increase in expression of CD69 and/or CD25 by the T lymphocytes by at least 20% as compared to unstimulated baseline control, thereby treating the infection in the subject, wherein the infection is a bacterial infection or a viral infection.